

Saya isytiharkan bahawa kandungan yang dibentangkan di dalam tesis ini adalah hasil kerja saya sendiri dan telah dijalankan di Universiti Sains Malaysia kecuali dimaklumkan sebaliknya. Tesis ini juga tidak pernah diserahkan untuk ijazah yang lain sebelum ini.

I declare that the content which is presented in this thesis is my own work which was done at Universiti Sains Malaysia unless informed otherwise. The thesis has not been previously submitted for any other degree.

Tandatangan calon:
Signature of student:

Nama calon:

MUHAMMAD ADNAN IQBAL

Name of student:

K/P / Passport No.: **FH1332401**

Disaksikan oleh:
Witnessed by:

Tandatangan Penyelia:
Signature of Supervisor:

Nama Penyelia:

**DR. ROSENANI BINTI S.M.
ANWARUL HAQUE**

Name of Supervisor:

K/P / Passport No.: **630805025720**

Dr. Rosenani S.M. Anwarul Haque
Pusat Pengajian Sains Kimia
Universiti Sains Malaysia
11800 Pulau Pinang

**SYNTHESIS, STRUCTURE AND *IN VITRO* ANTICANCER STUDIES OF
DINUCLEAR SILVER(I)-*N*-HETEROCYCLIC CARBENE COMPLEXES
DERIVED FROM XYLYL LINKED *BIS*-BENZIMIDAZOLIUM SALTS**

By

MUHAMMAD ADNAN IQBAL

Thesis submitted in fulfillment of the requirements

for the degree of

Doctor of Philosophy

January 2014

DEDICATION

I dedicate this thesis to:

*My beloved brother **Engineer Burhan Iqbal** in the honor of his unconditional financial and moral support with legitimate guidance throughout my career that has now brought me to this stage of success and prosperity.*

“Thanks a lot my brother”

ACKNOWLEDGMENTS

First and foremost, I would like to express my sincere thanks and gratitude to my supervisor, Dr. Rosenani A. Haque, not only for being a great supervisor but also for being a wonderful person. Without her help, guidance and incredible support this research project would have never been successful. Not to mention, of course, the numerous tours around Malaysia especially three days tour to Terengganu (2010), Damai lumut tour (2013), few BBQ parties and countless research group gatherings never let me feel that I am far away from my home. Thanks for such a great hospitality and for getting me through on time Dr. Rose. Thanks to Ayesha, Qia and Dine for such a friendly behaviour during my stay among you. It was like a family.

I express my deep sense of gratitude to the Dean (Prof. Wan Ahmad Kamil Mahmood) and Deputy Deans (Prof. Norita Mohamed and Prof. Madya Afidah Abdul Rahim) of school of chemical sciences for providing such a good research environment and necessary facilities.

Furthermore, I would like to express my thanks to my co-advisor, Dr. Amin Malik Shah Abdul Majid, for his contribution, knowledge and encouragement. My heartiest gratitude goes to Dr. Mohamed B. Khadeer Ahamed, a post doctoral fellow from Dr. Amin's lab., for his righteous friendship, felicitous guidance in biological studies and proof reading as well.

I am deeply thankful to IPS (USM) for financial support during my candidature [fellowship: USM.IPS/JWT/1/19 (JLD 6): P-KD0030/11(R)] and for allocating research attachment funds P-KM0018/10R-308/AIPS/415401 to carry out a part of my research in University of Western Australia, Perth, Australia. At the same time, I would like to express my sincere thanks to Dr. Muray V. Baker for inviting

me to work in his laboratory (UWA). I am also thankful to Dr. Lindsay Byrne, Professor Allan White and Dr. Brian Skelton for their expert guidance on NMR (LB) and X-ray crystallography during my stay in UWA.

I must also extend my thanks to Mr. Zahari for his assistance, advices and patience on NMR. To Mr. Ong and Mr. Azizo thank you for your help on FT-IR. I would like to thank to all the clerical and technical staff members of school of chemical sciences for their cooperation and help. My gratitude goes to Mustaqim and Wansin Loh from crystallography unit for solving crystal structures. Their timely efforts are much appreciated.

To everyone past and present from Dr. Rose's research group: Dr. Abbas, Mr. Mohammad Z. Ghdayeb, Siti Fatimah Nasri, Noorhafizah, Zetty Zulikha, Choo Szeyii (Suzy), Patrick and Tabinda thanks for all your assistance and for making lab a nice place to work in. I am grateful to Dr. Srinivasa for his assistance and help.

Many thanks to my parents for giving me the opportunity to take my education this far. To my brothers and sisters, especially Engineer Burhan Iqbal thanks for timely financial and moral support with appropriate guidance.

Finally thanks to my friends for being the wonderful people they are (those both here in Malaysia and over-seas); in particular Ihtisham, Dr. Khadeer, Ashfaq, Atif, Anas, Haroon, Rina, Mojde, Elham, Fatima J., Irfan, Shoaib, Rai mumtaz, and Usman.

TABLE OF CONTENTS

	Page
Dedication	ii
Acknowledgments	iii
Table of Contents	v
List of Tables	xiv
List of Figures	xv
List of Schemes	xxi
List of Abbreviations	xxii
Abstrak	xxiv
Abstract	xxvi
CHAPTER ONE-INTRODUCTION	1
1.1 The <i>N</i> -heterocyclic carbenes (NHCs)	1
1.2.1 Discovery of NHCs (Background)	2
1.2.2 The stability of NHCs	5
1.3 Syntheses of azolium salts: the NHC precursors	6
1.3.1 Nucleophilic substitution starting at the azole heterocycle	6
1.3.2 Multi-component reaction, building up the heterocycle with appropriate substituents in one step	7
1.4 Syntheses of NHC complexes (Discovery of M-NHC complexes)	8
1.5 Syntheses of silver(I)-NHC complexes	10
1.5.1 Free carbene route	10
1.5.2 Base in the presence of a silver salt	11
1.5.3 Transmetallation to silver(I)-NHC complexes	12
1.5.4 “Silver Base” route	13

1.6	Applications of silver(I)-NHC complexes	15
1.6.1	Ligand transfer chemistry	15
1.6.2	Catalysis	16
1.6.3	Biological	16
1.6.3.1	Silver a medically important metal	16
1.6.3.2	Benzimidazole: a medically important heterocyclic moiety	18
1.6.3.3	Cancer and metal-based drugs	20
1.6.3.4	Silver(I)-NHC complexes as potential anti-cancer metallodrugs	24
1.7	Objectives of the present work	27
	CHAPTER TWO-MATERIALS AND METHODS	29
2.1	Syntheses	29
2.1.1	Materials	29
2.1.2	Methods	29
2.1.2.1	Syntheses of <i>N</i> -alkylbenzimidazoles (1-11)	29
2.1.2.2	Syntheses of <i>bis</i> -benzimidazolium salts (12-44)	30
2.1.2.3	Syntheses of silver(I)-NHC complexes (45-77)	31
2.2	Characterisations	31
2.2.1	Fourier transform infrared (FT-IR) spectroscopy	31
2.2.2	Fourier transform nuclear magnetic resonance (FT-NMR) spectroscopy	32
2.2.3	X-ray crystallography	32
2.3	Biological studies	35
2.3.1	Anticancer	35
2.3.2	Anti-oxidant	37

2.3.3	Anti-inflammatory	38
CHAPTER THREE-RESULTS AND DISCUSSION		41
3.1	Syntheses of <i>N</i> -substituted benzimidazoles (1-11); General procedure	41
3.2	Syntheses of <i>para</i> -, <i>meta</i> -, <i>ortho</i> -xylyl linked <i>bis</i> -benzimidazolium salts; General procedure	44
3.3	Syntheses of dinuclear silver(I)-NHC complexes derived from <i>para</i> -/ <i>meta</i> -/ <i>ortho</i> -xylyl linked <i>bis</i> -benzimidazolium salts; General procedure	47
3.4	Characterisation	51
3.4.1	Melting points	51
3.4.2	FT-IR spectroscopy	53
3.4.3	NMR spectroscopy	58
3.4.4	X-ray crystallography	65
	3.4.4.1 Single crystals from the <i>para</i> -series	65
	3.4.4.2 Single crystals from the <i>meta</i> -series	78
	3.4.4.3 Single crystals from the <i>ortho</i> -series	87
	3.4.4.4 Comparison of benzene rings from benzimidazolium and xylyl units	93
3.5	Biological studies	104
3.5.1	<i>In vitro</i> anticancer studies against human colon cancer (HCT 116) cells	104
	3.5.1.1 <i>Para</i> -series compounds	108
	3.5.1.2 <i>Meta</i> -series compounds	116
	3.5.1.3 <i>Ortho</i> -series compounds	121
3.5.2	<i>In vitro</i> anticancer studies against leukemia (HL-60) cells	126
3.5.3	<i>In vitro</i> anticancer studies on human immortalized myelogenous leukemia (K562) cells	131
3.5.4	Anticancer mechanism of action and structure activity relationship (SAR)	135

3.5.5	Reasons of anti-oxidant and anti-inflammatory studies	137
3.5.6	Anti-oxidant studies	138
3.5.7	Anti-inflammatory studies	142
	CHAPTER FOUR-SUMMARY, IMPORTANT FINDINGS AND RECOMMENDATIONS FOR FUTURE WORK	147
4.1	Summary	147
4.1.1	Syntheses	147
4.1.2	Characterization	147
4.1.3	Biological studies	149
4.2	Important findings	151
4.3	Recommendations for future work	152
	CHAPTER FIVE- EXPERIMENTAL	155
5.1	Syntheses of <i>N</i> -alkylbenzimidazoles (1-12)	155
5.1.1	<i>N</i> -ethylbenzimidazole (1)	155
5.1.2	<i>N</i> -propylbenzimidazole (2)	155
5.1.3	<i>N</i> -butylbenzimidazole (3)	156
5.1.4	<i>N</i> -pentylbenzimidazole (4)	156
5.1.5	<i>N</i> -hexylbenzimidazole (5)	157
5.1.6	<i>N</i> -heptylbenzimidazole (6)	157
5.1.7	<i>N</i> -octylbenzimidazole (7)	158
5.1.8	<i>N</i> -nonylbenzimidazole (8)	158
5.1.9	<i>N</i> -decylbenzimidazole (9)	159
5.1.10	<i>N</i> -benzylbenzimidazole (10)	159
5.1.11	<i>N</i> - ^{<i>i</i>} propylbenzimidazole (11)	160
5.2	The <i>para</i> -xylyl linked <i>bis</i> -benzimidazolium salts (12-22)	160

5.2.1	3,3'-(1,4-phenylenebis(methylene))bis(1-ethylbenzimidazolium) dichloride (12.2Cl)	160
5.2.2	3,3'-(1,4-phenylenebis(methylene))bis(1-propylbenzimidazolium) dichloride (13.2Cl)	161
5.2.3	3,3'-(1,4-phenylenebis(methylene))bis(1-butylbenzimidazolium) bis(hexafluorophosphate) (14.2PF₆)	161
5.2.4	3,3'-(1,4-phenylenebis(methylene))bis(1-pentylbenzimidazolium) dibromide (15.2Br)	162
5.2.5	3,3'-(1,4-phenylenebis(methylene))bis(1-hexylbenzimidazolium) dichloride (16.2Cl)	163
5.2.6	3,3'-(1,4-phenylenebis(methylene))bis(1-heptylbenzimidazolium) bis(hexafluorophosphate) (17.2PF₆)	163
5.2.7	3,3'-(1,4-phenylenebis(methylene))bis(1-octylbenzimidazolium) dibromide (18.2Br)	164
5.2.8	3,3'-(1,4-phenylenebis(methylene))bis(1-nonylbenzimidazolium) dibromide (19.2Br)	165
5.2.9	3,3'-(1,4-phenylenebis(methylene))bis(1-decylbenzimidazolium) dibromide (20.2Br)	165
5.2.10	3,3'-(1,4-phenylenebis(methylene))bis(1-benzylbenzimidazolium) dichloride (21.2Cl)	166
5.2.11	3,3'-(1,4-phenylenebis(methylene))bis(1- <i>i</i> -propylbenzimidazolium) dibromide (22.2Br)	167
5.3	The <i>meta</i> -xylyl linked <i>bis</i> -benzimidazolium salts (23-33)	167
5.3.1	3,3'-(1,3-phenylenebis(methylene))bis(1-ethylbenzimidazolium) bis(hexafluorophosphate) (23.2PF₆)	167
5.3.2	3,3'-(1,3-phenylenebis(methylene))bis(1-propylbenzimidazolium) dibromide (24.2Br)	168
5.3.3	3,3'-(1,3-phenylenebis(methylene))bis(1-butylbenzimidazolium) bis(hexafluorophosphate) (25.2PF₆)	169
5.3.4	3,3'-(1,3-phenylenebis(methylene))bis(1-pentylbenzimidazolium) dibromide (26.2Br)	169
5.3.5	3,3'-(1,3-phenylenebis(methylene))bis(1-hexylbenzimidazolium) dibromide (27.2Br)	170
5.3.6	3,3'-(1,3-phenylenebis(methylene))bis(1-heptylbenzimidazolium) dibromide (28.2Br)	171

5.3.7	3,3'-(1,3-phenylenebis(methylene))bis(1-octylbenzimidazolium) dibromide (29.2Br)	172
5.3.8	3,3'-(1,3-phenylenebis(methylene))bis(1-nonylbenzimidazolium) dibromide (30.2Br)	173
5.3.9	3,3'-(1,3-phenylenebis(methylene))bis(1-decylbenzimidazolium) dibromide (31.2Br)	173
5.3.10	3,3'-(1,3-phenylenebis(methylene))bis(1-benzylbenzimidazolium) dibromide (32.2Br)	174
5.3.11	3,3'-(1,3-phenylenebis(methylene))bis(1- <i>i</i> -propylbenzimidazolium) bis(hexafluorophosphate) (33.2PF₆)	175
5.4	The <i>ortho</i> -xylyl linked <i>bis</i> -benzimidazolium salts (34-44)	176
5.4.1	3,3'-(1,2-phenylenebis(methylene))bis(1-ethylbenzimidazolium) dibromide (34.2Br)	176
5.4.2	3,3'-(1,2-phenylenebis(methylene))bis(1-propylbenzimidazolium) dibromide (35.2Br)	177
5.4.3	3,3'-(1,2-phenylenebis(methylene))bis(1-butylbenzimidazolium) bis(hexafluorophosphate) (36.2PF₆)	177
5.4.4	3,3'-(1,2-phenylenebis(methylene))bis(1-pentylbenzimidazolium) dibromide (37.2Br)	178
5.4.5	3,3'-(1,2-phenylenebis(methylene))bis(1-hexylbenzimidazolium) dibromide (38.2Br)	179
5.4.6	3,3'-(1,2-phenylenebis(methylene))bis(1-heptylbenzimidazolium) dibromide (39.2Br)	179
5.4.7	3,3'-(1,2-phenylenebis(methylene))bis(1-octylbenzimidazolium) dibromide (40.2Br)	180
5.4.8	3,3'-(1,2-phenylenebis(methylene))bis(1-nonylbenzimidazolium) dibromide (41.2Br)	181
5.4.9	3,3'-(1,2-phenylenebis(methylene))bis(1-decylbenzimidazolium) dibromide (42.2Br)	181
5.4.10	3,3'-(1,2-phenylenebis(methylene))bis(1-benzylbenzimidazolium) dibromide (43.2Br)	182
5.4.11	3,3'-(1,2-phenylenebis(methylene))bis(1- <i>i</i> -propylbenzimidazolium) dibromide (44.2Br)	182
5.5	Syntheses of Ag(I)-NHC complexes derived from <i>para</i> -xylyl linked <i>bis</i> -benzimidazolium salts (45-55)	183

5.5.1	1,4-bis(<i>N</i> -ethylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (45)	183
5.5.2	1,4-bis(<i>N</i> -propylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (46)	183
5.5.3	1,4-bis(<i>N</i> -butylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (47)	184
5.5.4	1,4-bis(<i>N</i> -pentylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (48)	185
5.5.5	1,4-bis(<i>N</i> -hexylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (49)	186
5.5.6	1,4-bis(<i>N</i> -heptylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (50)	186
5.5.7	1,4-bis(<i>N</i> -octylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (51)	187
5.5.8	1,4-bis(<i>N</i> -nonylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (52)	187
5.5.9	1,4-bis(<i>N</i> -decylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (53)	188
5.5.10	1,4-bis(<i>N</i> -benzylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (54)	189
5.5.11	1,4-bis(<i>N</i> - <i>i</i> -propylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (55)	189
5.6	Ag(I)-NHC complexes derived from <i>meta</i> -xylyl linked <i>bis</i> -benzimidazolium salts (56-66)	189
5.6.1	1,3-bis(<i>N</i> -ethylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (56)	190
5.6.2	1,3-bis(<i>N</i> -propylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (57)	191
5.6.3	1,3-bis(<i>N</i> -butylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (58)	191
5.6.4	1,3-bis(<i>N</i> -pentylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (59)	192
5.6.5	1,3-bis(<i>N</i> -hexylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (60)	

		192
5.6.6	1,3-bis(<i>N</i> -heptylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (61)	193
5.6.7	1,3-bis(<i>N</i> -octylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (62)	194
5.6.8	1,3-bis(<i>N</i> -nonylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (63)	195
5.6.9	1,3-bis(<i>N</i> -decylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (64)	195
5.6.10	1,3-bis(<i>N</i> -benzylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (65)	196
5.6.11	1,3-bis(<i>N</i> - <i>i</i> -propylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (66)	197
5.7	Ag(I)-NHC complexes derived from <i>ortho</i> -xylyl linked <i>bis</i> - benzimidazolium salts (67-77)	198
5.7.1	1,2-bis(<i>N</i> -ethylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (67)	198
5.7.2	1,2-bis(<i>N</i> -propylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (68)	198
5.7.3	1,2-bis(<i>N</i> -butylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (69)	199
5.7.4	1,2-bis(<i>N</i> -pentylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (70)	200
5.7.5	1,2-bis(<i>N</i> -hexylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (71)	201
5.7.6	1,2-bis(<i>N</i> -heptylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (72)	201
5.7.7	1,2-bis(<i>N</i> -octylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (73)	202
5.7.8	1,2-bis(<i>N</i> -nonylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (74)	203
5.7.9	1,2-bis(<i>N</i> -decylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexaflourophosphate) complexes (75)	204
5.7.10	1,2-bis(<i>N</i> -benzylbenzimidazol-ylmethyl)	

benzene-disilver(I) bis(hexafluorophosphate) complexes (76)	204
5.7.11 1,2-bis(<i>N</i> - <i>i</i> -propylbenzimidazol-ylmethyl) benzene-disilver(I) bis(hexafluorophosphate) complexes (77)	205
REFERENCES	207
APPENDICES A-Z and AA	225
PUBLICATIONS AND CONFERENCES	252

LIST OF TABLES

		Page
Table 3.1:	Crystal Data and Structure Refinement Details for <i>Para</i> -Series Salts 12 .PF ₆ , 16 .2Br and Complexes 45 .2Br, 49 .2PF ₆ , 51 .2PF ₆ .	67
Table 3.2:	Crystal Data and Structure Refinement Details for <i>Meta</i> -Series Salts 23 .PF ₆ , 25 .2Br, 32 .2Br and Complexes 56 .2PF ₆ , 58 .2PF ₆ .	79
Table 3.3:	Crystal Data and Structure Refinement Details for <i>Ortho</i> -Series Salts 38-41 .2Br.	89
Table 3.4:	Crystal Data and Structure Refinement Details for Salts 22 .2PF ₆ , 33 .2PF ₆ , 44 .2Br.	94
Table 3.5:	Crystal Data and Structure Refinement Details for Salts 13 .2PF ₆ , 24 .2PF ₆ , 35 .2Br.	100
Table 3.6:	IC ₅₀ Values of <i>Para</i> -, <i>Meta</i> -, <i>Ortho</i> -Xylyl Linked <i>Bis</i> -Benzimidazolium Salts and Respective Ag(I)-NHC Complexes against HCT 116 Cell Line.	107
Table 3.7:	IC ₅₀ Values of <i>Para</i> -xylyl Linked <i>Bis</i> -benzimidazolium Salts (12-15 and 21) and Respective Silver(I) NHC Complexes (45-46 and 54) against HL-60 Cell Line (Acute Promyelocytic Leukemia).	130
Table 3.8:	IC ₅₀ Values of <i>Para</i> -xylyl Linked <i>Bis</i> -benzimidazolium Salts (18-20) and Respective Silver(I) NHC Complexes (51-53) against K562 Cell Line (Chronic Myelogenous Leukemia).	134
Table 3.9:	%Age Inhibition Values of Ligands (18-20) and their Complexes (52-54) for DPPH Analysis.	141

LIST OF FIGURES

	Page
Figure 1.1: Types of NHCs based on ring size with year of discovery. Orbital view of electron pair in a sp^2 -hybridized carbon with vacant p -orbital and π -donor N-atoms.	1
Figure 1.2: Formation of dimeric entetraamine II=II instead of free NHC II .	2
Figure 1.3: Attempt to synthesize free carbene IV from azolium salt III .	3
Figure 1.4: Arduengo's first stable N -heterocyclic carbene VI .	4
Figure 1.5: The reported methodologies for syntheses of the free NHCs.	4
Figure 1.6: Orbital (a) and resonance (b) representations of electronic stabilization in imidazole-2-ylidenes.	5
Figure 1.7: The orbital representation of singlet and triplet carbenes. In singlet carbenes unshared electrons are present in the same orbital whereas in triplet carbenes these electrons are present in two different orbitals.	6
Figure 1.8: General representation of syntheses of benzimidazolium salts by nucleophilic substitution.	7
Figure 1.9: General representation of syntheses of imidazolium salts by multi-components reaction.	7
Figure 1.10: General representation of multicomponent cyclization and N -alkylation.	8
Figure 1.11: Öfele's chromium-NHC complex.	8
Figure 1.12: Wanzlick's mercury(II)-NHC complex.	9
Figure 1.13: Syntheses of first silver N -heterocyclic carbene complex (1993).	11
Figure 1.14: Wang and Lin's method of base in presence of silver salt.	11
Figure 1.15: Transmetallation from tungsten(0) NHC to Ag and dissociation of silver complexes.	12
Figure 1.16: Syntheses of silver N -heterocyclic carbene complexes using silver oxide.	13
Figure 1.17: (a) Syntheses of silver-NHC polymer using AgOAc and (b) Syntheses of bridging complexes using Ag_2CO_3 .	14

Figure 1.18:	Representation of benzimidazole moiety and numbering.	18
Figure 1.19:	Benzimidazole derivatives tested against various types of cancer.	20
Figure 1.20:	Diagram showing malignant tumor.	21
Figure 1.21:	Worldwide approved platinum-based anticancer drugs.	22
Figure 1.22:	Examples of some transition metal complexes having potential anticancer properties.	23
Figure 1.23:	Silver(I)-NHC complexes tested for their anticancer properties by Youngs et al.	25
Figure 1.24:	Examples of symmetric and unsymmetrically substituted Ag(I)-NHC complexes reported by Tacke et al.	25
Figure 1.25:	Silver(I)-NHC complexes tested for cytotoxicity on MCF-7 cells by Gautier's team reporting the cytotoxicity of a compound decreases with increase in 1,3-substitution bulk.	26
Figure 1.26:	Silver(I)-NHC complexes with different coordination motives studied for their anticancer potential so far (A-C). Structure D has been designed for current study, the un-specified positions represent <i>ortho/meta/para</i> units. R is either alkyl or aryl substitution.	28
Figure 2.1:	Evaporation method of growing single crystals.	33
Figure 2.2:	Vapour diffusion method of growing single crystals.	33
Figure 2.3:	Images of single crystals of compounds 23 .2PF ₆ (a) and 28 .2Br (b) taken under an inverted phase-contrast microscope with a digital camera. Figure (c) shows single and multiple crystals. Scale in figures is 2000 μm.	34
Figure 3.1:	Pictorial schematic representation for the syntheses of <i>N</i> -alkylated benzimidazoles (1-11).	43
Figure 3.2:	Pictorial schematic representation for the syntheses of <i>para/meta/ortho</i> -xylyl linked <i>bis</i> -benzimidazolium salts (12-33).	45
Figure 3.3:	Work up procedure for <i>meta</i> -xylyl linked <i>bis</i> -benzimidazolium salts (23-33). (a) Reaction mixture containing product, (b) sticky product decanting. (c) Reaction mixture containing product, (d) non-sticky product (solid) after decanting (c).	47
Figure 3.4:	Pictorial schematic representation for the syntheses of dinuclear Ag(I)-NHC complexes.	48

Figure 3.5:	Dinuclear Ag(I)-NHC complexes 49 (A), 50 (B), and 73 (C).	49
Figure 3.6:	Melting point trends of <i>para</i> -series ligands (L. para) and complexes (C. para).	52
Figure 3.7:	Melting point trends of <i>meta</i> -series ligands (L. meta) and complexes (C. meta).	52
Figure 3.8:	Melting point trends of <i>ortho</i> -series ligands (L. ortho) and complexes (C. ortho).	52
Figure 3.9:	FT-IR overlay spectra of benzimidazole and selected <i>N</i> -alkylated benzimidazoles.	54
Figure 3.10:	FT-IR spectra (overlay) of selected <i>para</i> -/ <i>meta</i> -/ <i>ortho</i> -xylyl linked <i>bis</i> -benzimidazolium dibromides (16 , 18 , 20 / 27 , 29 , 31 / 38 , 40 , 41) highlighting, C-H _{aliph} stretching 2 , & C _{arom} -N _{benzimi} 1 .	56
Figure 3.11:	FT-IR spectra (overlay) of Ag-NHC complexes (49 , 51 , 53 / 60 , 62 , 64/71 , 73 , 75) highlighting C _{arom} -N _{benzimi} stretch 1 after successful reaction. The figure shows that a “ <i>four fingers (f.fs.)</i> ” pattern appears on FT-IR spectrum for each Ag-NHC complex. This information can be used as primary confirmation of successful syntheses.	57
Figure 3.12:	¹ H NMR spectra (<i>d</i> ₃ -acetonitrile, 300 MHz) indicating the changes in chemical shifts after successful reaction between (a) propyl bromide and benzimidazole to obtain (b) <i>N</i> -propylbenzimidazole.	59
Figure 3.13:	¹ H NMR spectra (<i>d</i> ₆ -DMSO, 500 MHz) indicating the changes in chemical shifts after successful reaction between (a) 13.2Cl and Ag ₂ O to get (b) dinuclear Ag-NHC complex 46.2PF₆ . “*” acetone in <i>d</i> ₆ -DMSO and “**” hydrated water molecules.	61
Figure 3.14:	¹³ C NMR spectra (<i>d</i> ₆ -DMSO, 125.76 MHz) indicating the changes in chemical shifts and appearance of two doublets after successful reaction between (a) 13.2Cl and Ag ₂ O to get dinuclear Ag-NHC complex (b) 46.2PF₆ . *Naturally occurring Silver (Ag) is composed of the two stable isotopes ¹⁰⁷ Ag and ¹⁰⁹ Ag with ¹⁰⁷ Ag being the more abundant (51.84%). <i>J</i> _{109Ag-C} = 209.875 Hz. <i>J</i> _{107Ag-C} = 181.125 Hz.	62
Figure 3.15:	The most significant changes in ¹ H and ¹³ C NMR spectra (<i>d</i> ₆ -DMSO, 500 MHz & 125.76 MHz) chemical shifts after successful reaction between 13.2Cl and Ag ₂ O to get dinuclear Ag-NHC complex 46.2PF₆ .	63

Figure 3.16:	Relative deshielding of methylene groups, attached directly to benzimidazolium units in ^1H and ^{13}C NMR.	64
Figure 3.17:	Molecular structures of <i>bis</i> -benzimidazolium salt 12.2PF₆ (a) and respective dinuclear Ag(I)-NHC complex 45.2PF₆ (b) with 50% probability displacement ellipsoids.	68
Figure 3.18:	Comparison of bond angles and bond lengths between ligand 12.2PF₆ and respective dinuclear Ag(I)-NHC complex 45.2PF₆ .	69
Figure 3.19:	Molecular structures of <i>bis</i> -benzimidazolium salt 16.2Br (a) and respective complex 49.2PF₆ (b) with 50% probability displacement ellipsoids.	71
Figure 3.20:	Two additional views of molecular structure of complex 49.2PF₆ . The atomic labels have been removed for the clarity of picture.	72
Figure 3.21:	Comparison of bond angles and bond lengths between ligand 16.2Br and respective dinuclear Ag(I)-NHC complex 49.2PF₆ .	73
Figure 3.22:	Molecular structure of complex 54.2PF₆ with 50% probability displacement ellipsoids. H atoms were removed for clarity of structure.	76
Figure 3.23:	Crystal packing of 54.2PF₆ . Intermolecular hydrogen bonds are shown as dashed lines.	76
Figure 3.24:	Selected bond angles and bond lengths of complex 54.2PF₆ .	77
Figure 3.25:	ORTEP picture of benzimidazolium salt 23 (a) and ORTEP picture of carbene complex 56 (b) with displacement ellipsoids drawn at 50% probability.	80
Figure 3.26:	Molecular structures of <i>bis</i> -benzimidazolium salt 25.2Br (a) and respective complex 58.2PF₆ (b) with 50% probability displacement ellipsoids.	83
Figure 3.27:	Molecular structures of <i>bis</i> -benzimidazolium salt 32.2Br (a) and its packing (triclinic, b) with 50% probability displacement ellipsoids.	86
Figure 3.28:	Molecular structures of 38.2Br (<i>N</i> -hexyl, a), 39.2Br (<i>N</i> -heptyl, b), 40.2Br (<i>N</i> -octyl, c), and 41.2Br (<i>N</i> -nonyl, d) drawn with 50% probability displacement ellipsoids.	90
Figure 3.29:	The ORTEP pictures of <i>bis</i> -benzimidazolium salts 22.2PF₆ (a), 33.2PF₆ (b), and 44.2PF₆ (c) with displacement ellipsoids drawn at 50% probability.	95

Figure 3.30:	A comparisons of bond angles and bond lengths for benzene rings of benzimidazolium and xylyl units in <i>bis</i> -benzimidazolium salts.	96
Figure 3.31:	The ORTEP pictures of <i>bis</i> -benzimidazolium salts 13.2Cl (a) , 24.2PF₆ (b) , and 35.2Br (c) with displacement ellipsoids drawn at 50% probability.	101
Figure 3.32:	A comparison of bond angles and bond lengths for benzene rings of benzimidazolium and xylyl units in <i>bis</i> -benzimidazolium salts (Data collected from respective single crystal).	102
Figure 3.33:	This type of cancer starts as a tumor as shown in two figures (right side) and at this stage if not treated properly, it extends as cancer.	104
Figure 3.34:	Marketing drugs for the treatment of cancer related to colon and rectum.	105
Figure 3.35:	Chemical structures and IC ₅₀ (μM) values of Au(I)-NHC complexes tested against human colon cancer cell line (HCT 116).	106
Figure 3.36:	Dose-dependent antiproliferative effect of synthetic ligands (12-21) on human colorectal tumor cells (HCT 116).	110
Figure 3.37:	HCT 116 cell images at 48 h after treatment with the samples. The cancer cells from the control group have been shown in figure A whereas figures B - L present the cancer cells treated with <i>para</i> -series salts 12-22 .	111
Figure 3.38:	HCT 116 cell images at 48 h after treatment with the samples. Figure A shows cancer cells treated with the standard drug 5-fluorouracil whereas figures B-L present the cells treated with <i>para</i> -series complexes 45-55 .	111
Figure 3.39	Dose-dependent antiproliferative effect of <i>meta</i> -series ligands (23-33) and respective silver complexes (56-66) on human colorectal tumor cells (HCT 116).	117
Figure 3.40:	HCT 116 cell images at 48 h after treatment with the <i>meta</i> -series salts 23-33 .	118
Figure 3.41:	HCT 116 cell images at 48 h after treatment with the <i>meta</i> -series complexes 56-66 .	118
Figure 3.42:	Dose-dependent antiproliferative effect of <i>ortho</i> -series ligands (34-44) and respective silver complexes (67-77) on human colorectal tumor cells (HCT 116).	122

Figure 3.43:	HCT 116 cell images at 48 h after treatment with the <i>ortho</i> -series salts 34-44 .	123
Figure 3.44:	HCT 116 cell images at 48 h after treatment with the <i>ortho</i> -series complexes 67-77 .	123
Figure 3.45:	Idarubicin, a marketing drug from acute promyelocytic leukemia.	127
Figure 3.46:	Dose-dependent antiproliferative effect of synthetic ligands (12-14) and respective metal complexes (45-47) on human leukaemia cells (HL-60).	127
Figure 3.47:	HL-60 cell images were taken under an inverted phase-contrast microscope at $\times 200$ magnification with a digital camera at 48 h after treatment with the samples.	128
Figure 3.48:	The Au(I)-NHC compound tested against acute promyelocytic leukemia (HL-60 cell line).	129
Figure 3.49:	The marketing drugs for the treatment of chronic myelogenous leukemia.	131
Figure 3.50:	Dose-dependent antiproliferative effect of synthetic ligands (18-20) and respective metal complexes (51-53) on Chronic Myelogenous Leukemia cells (K562).	132
Figure 3.51:	Human erythromyeloblastoid leukemia cell line K562 cell images were taken under an inverted phase-contrast microscope at $\times 200$ magnification with a digital camera at 48 h after treatment with the samples.	133
Figure 3.52:	DPPH radical trap mechanism of action.	139
Figure 3.53:	Comparison between the antioxidant efficacy of treatment groups and Gallic acid at the maximum used concentration (400 μ M). In figure, x represents pure benzimidazole.	140
Figure 3.54:	Schematic presentation of inflammation and proposed anti-inflammatory mechanism of <i>bis</i> -benzimidazolium salt (16.2Br) and respective dinuclear silver(I)-NHC complex (49.2PF₆).	143
Figure 3.55:	Phosphine and benzothiazole coordinated silver(I) complexes successfully applied against inflammation <i>in vivo</i> for the burnt surfaces of animals for 21 days.	144
Figure 3.56:	% inhibition of NO, TNF- α and IL-1 production in U-937 cells by 16.2Br and 49.2PF₆ at the maximum concentration of 200 μ M/ml.	146

LIST OF SCHEMES

Scheme 3.1:	General scheme for syntheses of N-alkylated benzimidazoles (1-11), <i>bis</i> -benzimidazolium salts (12-45), and Ag(I)-NHC complexes (45-77).	42
Scheme 3.2:	Syntheses of <i>N</i> -alkylated benzimidazoles (1-11).	44
Scheme 3.3:	Syntheses of <i>para</i> -xylyl linked <i>bis</i> -benzimidazolium salts (12-22).	45
Scheme 3.4:	Syntheses of <i>meta</i> -xylyl linked <i>bis</i> -benzimidazolium salts (23-33).	46
Scheme 3.4:	Syntheses of <i>ortho</i> -xylyl linked <i>bis</i> -benzimidazolium salts (34-44).	46
Scheme 3.5:	Syntheses of Ag(I)-NHC complexes (44-77) using <i>bis</i> benzimidazolium halides as starting material.	50

LIST OF ABBREVIATIONS

NHC	<i>N</i> -heterocyclic carbene
Ar	Arene
DMSO	Dimethyl sulfoxide
THF	Tetrahydrofuran
DCM	Dichloromethane
OAc	Acetate
h	Hour(s)
Anal.	Analysis
Calc.	Calculated
nJ	Nuclear spin-spin coupling constant through bonds
Å	Angstrom
<i>h</i>	Crystallographic index
α	Crystallographic unit-cell angle between axes <i>b</i> and <i>c</i>
β	Crystallographic unit-cell angle between axes <i>a</i> and <i>c</i>
<i>a</i>	Crystallographic unit cell axis <i>a</i>
<i>b</i>	Crystallographic unit cell axis <i>b</i>
<i>c</i>	Crystallographic unit cell axis <i>c</i>
HIFBS	Heat inactivated foetal bovine serum
PBS	Phosphate buffer saline
PS	Penicillin/streptomycin
MTT	Methylthiazolyldiphenyl-tetrazolium bromide
µl	Microliter
OD	Optical density
DPPH	2,2-diphenyl-1-picrylhydrazyl
PMA	Phorbol 12-myristate 13-acetate
LPS	Lipopolysachharide
ELISA	Enzyme linked immunosorbant assay
IL-1	Interleukin-1
TNF- α	Tumor necrosis factor- α
COX	Cyclooxygenase
IC ₅₀	Concentration of test substance to achieve 50% inhibition

RPMI	Roswell Park Memorial Institute (media was name on the name of developer, More et al., at Roswell Park Memorial Institute)
Mes	Mesityl
dppe	1,2-Bis(diphenylphosphino)ethane
RT	Room temperature
ORTEP	Oak Ridge Thermal Ellipsoid Plot
cod	1,5-cyclooctadiene
qnt	quintet
br.m	broad multiplet

**SINTESIS, STRUKTUR DAN KAJIAN *IN VITRO* ANTIKANSER
KOMPLEKS DINUKLEAR ARGENTUM *N*-HETEROSIKLIK KARBENA
DIPEROLEHI DARI KAITAN XYLYL GARAM *BIS*-BENZIMIDAZOLIUM**

ABSTRAK

Kajian ini menerangkan tentang sintesis tiga siri garam bis-benzimidazolium sebagai prekursor *N*-heterosiklik karbena (NHC) dan kompleks mereka dengan ion argentum(I) untuk mendapatkan kompleks argentum(I)-NHC. Setiap siri garam adalah terbitan samada daripada *para*-, *meta*-, atau *orto*-xilin sistem berangkai yang mempunyai gantian etil-desil, benzil dan *i*-propil di kedudukan 3 pada cincin benzimidazolium. Kesemua garam dan kompleks telah dicirikan oleh spektroskopi (FT-IR, ¹H and ¹³C NMR), analisis unsur (CHN) dan teknik pembelauan sinar-X kristal tunggal. Semua kompleks telah disediakan melalui tindakbalas *in situ* diantara Ag₂O dengan garam bis-benzimidazolium yang sepadan dan telah diuji dengan sel kanser kolon manusia. Bagaimana pun hanya garam dan kompleks terpilih telah diuji selanjutnya dengan promielositik akut leukemia dan sel leukemia mielogenus abadi. Garam dan kompleks ini menunjukkan potensi aktiviti antikanser menentang kesemua sel kanser yang diuji. Walaubagaimana pun, kompleks terbukti mempunyai sitotoksikiti lebih tinggi berbanding dengan garamnya. Selanjutnya, aktiviti anti-radang bagi *N*-heksil gantian *para*-xylyl berangkai garam bis-benzimidazolium dan kompleksnya telah diuji. Memandangkan kanser dan keradangan adalah berkait antara satu sama lain, maka kita mencadangkan bahawa dadah yang mempunyai potensi antikanser mungkin juga mempunyai potensi terhadap anti-radang. Menariknya, kedua-dua sebatian ini terbukti mempunyai aktiviti anti-radang. Selain itu, tindakan mekanisma telah diterokai dan didapati sebatian inhibitor

siklooksigenase-1 dan siklooksigenase-2 serta sitokin (interleukin-1, α -faktor nekrosis tumor, and nitrik oksida) adalah penghalang. Dalam semua kes didapati kompleks mempunyai hasil yang lebih baik dan berganda berbanding dengan garam masing-masing.

**SYNTHESIS, STRUCTURE AND *IN VITRO* ANTICANCER STUDIES OF
DINUCLEAR SILVER(I)-*N*-HETEROCYCLIC CARBENE COMPLEXES
DERIVED FROM XYLYL LINKED *BIS*-BENZIMIDAZOLIUM SALTS**

ABSTRACT

The current study was aimed to synthesize three series of *bis*-benzimidazolium salts (**12-44**) as stable *N*-heterocyclic carbene (NHC) precursors and their complexation with silver(I) ions in order to obtain dinuclear silver(I)-NHC complexes (**45-77**). Each series of salts was derived either from *para*-, *meta*-, or *ortho*-xylene linked systems having ethyl-decyl, benzyl and *i*-propyl substituents at number 3-position of benzimidazolium ring. The salts and complexes were characterized by spectroscopy (FT-IR, ¹H and ¹³C NMR), elemental analysis (CHN) and single crystal X-ray diffraction techniques. All the complexes were prepared by *in situ* reaction of Ag₂O with the corresponding *bis*-benzimidazolium salts and were tested against human colon cancer cells. Selected salts (**12-14**, **18-20**, **21**) and respective complexes (**45-47**, **29-31**, **54**) were further tested against acute promyelocytic leukaemia and immortalized myelogenous leukaemia cells. The compounds showed potential anticancer activity against all the tested cancer cell lines. Moreover, complexes exhibited higher cytotoxicity compared to respective salts. The anticancer potential of compounds increased with the increase in chain length at position 3-nitrogen. Furthermore, considering the triangular relationship among cancer, inflammation and oxidation, selected compounds were further tested for possible anti-oxidant and anti-inflammatory activities. The tested compounds did not show anti-oxidant behaviour however, proved to have anti-inflammatory activity comparable to the standards used. Additionally, the anti-inflammatory mechanism of action was explored and the compounds were found cyclooxygenase-1 and

cyclooxygenase-2 inhibitors as well as cytokines (interleukin-1, tumor necrosis factor- α , and nitric oxide) blockers. In all cases the complexes were found to have many fold better results compared to the respective salts concluding that silver imparts an important role against cancer and inflammation.

CHAPTER ONE

INTRODUCTION

1.1 The *N*-heterocyclic carbenes

N-heterocyclic carbenes (NHCs) are versatile class of ligands which have various types based on ring size, starting from the carbenes derived from four membered *N*-heterocycles and extend upto seven membered *N*-heterocycles (Figure 1.1) (Hahn and Jahnke, 2008), among which perhaps five membered NHCs are the most widely studied carbenes (Bates et al., 2009).




Figure 1.1: Types of NHCs based on ring size with year of discovery. Orbital view of electron pair in a sp^2 -hybridized carbon with vacant *p*-orbital and π -donor N-atoms.

In these carbenes a divalent carbon moiety is flanked by two π -donor nitrogen atoms. The strong σ -donating and weak π -accepting properties of NHCs have

rendered them as excellent ligands not only for d-block elements (Arnold and Pearson, 2007) but also for f-block elements (Arnold and Casely, 2009a; Arnold and Casely, 2009b; Evans, 2007; Evans et al., 1981).

1.2.1 Discovery of NHCs (Background)

Discussion about NHCs was initiated by Wanzlick in 1960 by his report on the α -elimination of chloroform from **I** to get free NHC **II** (Wanzlick and Schikora, 1960). However, Wanzlick could never isolate **II** and always obtained its dimer **II=II** (Hahn and Jahnke, 2008) (Figure 1.2). Wanzlick also tried the cleavage of dimeric entetraamine according to $\text{II=II} \rightarrow 2 \times \text{IV}$ using cross-metathesis method but failed (Lemal et al., 1964; Winberg et al., 1965).




Figure 1.2: Formation of dimeric entetraamine **II=II** instead of free NHC **II**.

Around 1970, Wanzlick decided to change the starting material for the generation of free NHC. He tried to prepare the free carbene **IV** by deprotonation of 1,3,4,5-tetraphenylimidazolium perchlorate **III** with $\text{KO}t\text{Bu}$ (Schönherr and Wanzlick, 1970) (Figure 1.3), because at that time it was already known that azolium cations react in presence of base-catalyzed medium (Fild et al., 1964; Olofson et al., 1964; Staab et al., 1964). The free carbene again could not be isolated. However, generation of free NHC **IV** by this method was detected as the intermediate product

from the identification of some of its reaction products with water or mercuric acetate (Schönherr and Wanzlick, 1970).




Figure 1.3: Attempt to synthesize free carbene **IV** from azolium salt **III**.

Up to this point, a concept had already developed that a NHC can be synthesized but only as an intermediate and can't be isolated as a stable product for further laboratory or commercial use. However, Arduengo believed that the intermediate carbene must not be as unstable as was being assumed by scientific community (Arduengo and Krafczyk, 1998). Finally in 1991, Arduengo and co-workers synthesized and isolated the first crystallographically elucidated NHC **VI** from an azolium salt **V** in presence of sodium hydride and catalytic amount of DMSO using THF as reaction medium (Figure 1.4) (Arduengo et al., 1991). This carbene was found to have a unique stability at room temperature in the absence of oxygen and moisture. Later on, in 1998 Arduengo et al., also prepared, isolated, and crystallographically characterized carbene **IV** (Figure 1.3) that Wanzlick could not isolate in 1968 (Arduengo III et al., 1998).




Figure 1.4: Arduengo's first stable *N*-heterocyclic carbene **VI**.

The discovery of first stable carbene **VI** led to significant interest in the field of carbene chemistry. To date, different methods for the syntheses of NHCs have been reported, which include the desulfuration of imidazole-2(3H)-thiones (Kuhn and Kratz, 1993) and methanol elimination by thermolysis of 5-methoxy-1,3,4-triphenyl-4,5-dihydro-1H-1,2,4-triazoles (Figure 1.5) (Enders et al., 1995; Hahn and Jahnke, 2008).




Figure 1.5: The reported methodologies for syntheses of the free NHCs.

1.2.2 The stability of NHCs

Initially, many researchers thought that the unique stability of the NHC, synthesized by Arduengo, was due to the bulky *N*-adamantyl substituents which prevent the dimerisation of the carbene due to steric hindrance. However, Arduengo's syntheses of another stable carbene with *N*-methyl substituents proved otherwise (Arduengo et al., 1992). Arduengo justified that the electronic contributions are the main stabilizing factors which involve electron donation from the adjacent nitrogen atoms to the vacant $p(\pi)$ orbital of the carbene carbon (Figure 1.6).




Figure 1.6: Orbital (a) and resonance (b) representations of electronic stabilization in imidazole-2-ylidenes.

Hence the role of *N*-substituents is unique, for example the π -donor substituents increase $p\pi$ character of the singlet carbene (see Figure 1.7) by transferring π electrons to the empty p -orbitals of the carbene carbon (Bourissou et al., 1999) and consequently, the bulky substituents on the nitrogen atoms contribute to the stability of the carbenes (Bourissou et al., 1999; Hahn et al., 2000). Furthermore, due to higher electronegativity of nitrogen as compare to carbon atom,

charge density is considered to be inductively withdrawn through the σ -framework, stabilizing the carbene lone pair (Arduengo et al., 1992).




Figure 1.7: The orbital representation of singlet and triplet carbenes. In singlet carbenes unshared electrons are present in the same orbital whereas in triplet carbenes these electrons are present in two different orbitals.

1.3 Syntheses of azolium salts: the NHC precursors

Azolium salts are generally synthesized by two common synthetic routes (Weskamp et al., 2000):

1.3.1 Nucleophilic substitution starting at the azole heterocycle.

In this route, azole (imidazole, benzimidazole, triazole etc) heterocycle is first reacted with a strong base (eg., KOH, NaOH) to get potassium or sodium azolide that is subsequently reacted with one equivalent of alkyl or aryl halide in appropriate solvent to collect the 1-alkyl or 1-aryl azole (Herrmann, 2002; Starikova et al., 2003b). 1-substituted azole is then reacted with one equivalent of alkyl or aryl halide of interest at position 3-nitrogen (Figure 1.8). This method allows the syntheses of unsymmetrical imidazolium salts by stepwise alkylation.




Figure 1.8: General representation of syntheses of benzimidazolium salts by nucleophilic substitution.

1.3.2 Multi-components reaction, building up the heterocycle with the appropriate substituents in one step.

In this route, primary amines, glyoxal, and formaldehyde are reacted in the presence of Brønsted acid as one pot reaction (Figure 1.9) (Böhm et al., 2000; Herrmann et al., 1996).




Figure 1.9: General representation of syntheses of imidazolium salts by multi-components reaction.

This flexible route is suitable for the syntheses of symmetrical 1,3-substituted azolium salts. However, unsymmetrical substituted azolium salts can also be synthesized by combining a multicomponent cyclization with *N*-alkylation reaction (Gridnev and Mihaltseva, 1994). According to this method, an initial cyclization at pH 1 yields an *N*-alkylazolium salt that is subsequently alkylated at second nitrogen atom in presence of base to give the asymmetrically substituted derivative (Figure 1.10).




Figure 1.10: General representation of multicomponent cyclization and *N*-alkylation.

The 1,3-alkyl/aryl-substitutions facilitate the lone pairs at nitrogen atoms to resonate on NCN framework. This phenomenon makes position 2-hydrogen acidic to be easily removed by a suitable base (Figure 1.10). In the current study, syntheses of *bis*-benzimidazolium salts were carried out according to the route 1.3.1 (page 6) with minor modifications.

1.4 Syntheses of NHC complexes (Discovery of M-NHC complexes)

Although, the first stable *N*-heterocyclic carbene was only isolated in 1991, its complexation with metals (Cr and Hg) was already achieved 22 years earlier by Öfele and Wanzlick (Öfele, 1968; Wanzlick and Schönherr, 1968) independently.

Öfele and co-workers were actually trying to synthesize some dihydro complexes by heating the hydropentacarbonyl chromium heterocyclic salt. They found that there is an unusual reaction when imidazolium salts used, which lead to the formation of an *N*-heterocyclic carbene chromium complex shown in Figure 1.11.




Figure 1.11: Öfele's chromium-NHC complex.

At the same time, Wanzlick and Schönherr synthesized a mercury(II)-NHC complex by a direct reaction between 1,3-diphenylimidazolium perchlorate and mercury(II) acetate (Figure 1.12) in DMSO. In this reaction, the acetate ions play the main role that is the *in situ* deprotonation of the imidazolium salt and release of the acetic acid to form the complex. Later on, the metal acetate route was adopted as one of the general routes for the syntheses of several transition metal-NHC complexes.




Figure 1.12: Wanzlick's mercury(II)-NHC complex.

Since the discovery of Öfele's Cr(III)-NHC and Wanzlick's Hg(II)-NHC complexes that, NHCs have been widely synthesized and used in organometallic and inorganic chemistry. The first comprehensive review about the synthetic methods of free NHCs and their coordination chemistry was compiled by Herrmann and Köcher about 15 years ago (Herrmann and Köcher, 1997) and the latest one by Hahn and Jahnke about 5 years ago (Hahn and Jahnke, 2008) which additionally describes the types of NHCs. Catalytic applications of this class have been reviewed by Herrmann (Herrmann, 2002), Crudden (Crudden and Allen, 2004), and Glorius (Glorius, 2007) whereas biological applications by K-Nebioglu (Kascatan-Nebioglu et al., 2007), Garrison (Garrison and Youngs, 2005), and recently by Teyssot (Teyssot et al., 2009a). Several methods have been explored for the preparation of NHC complexes (Enders and Gielen, 2001; Peris and Crabtree, 2003; Weskamp et al., 2000). To date, NHCs have been incorporated to almost all the transition metals of periodic table

using different synthetic routes (Arnold and Pearson, 2007; Evans, 2007). A brief review by Weskamp describes various synthetic routes for bonding transition metals to NHCs (Weskamp et al., 2000).

1.5 Syntheses of silver(I)-NHC complexes

Syntheses of silver(I)-NHC complexes have been reported mainly by four routes: **(1.5.1)** generation of free carbene from azolium salt and subsequent reaction with a silver salt, (Arduengo et al., 1993; Caballero et al., 2001a; Chung, 2002; Fox et al., 2002), **(1.5.2)** *In situ* reaction of azolium salts with basic silver reagents, (Arnold, 2002; Chianese et al., 2004; Danopoulos et al., 2003; Guerret et al., 2000; Guerret et al., 1997; Herrmann et al., 2004; Hu et al., 2004; Mayr et al., 2004; Melaiye et al., 2005; Tulloch et al., 2000; Wanniarachchi et al., 2004), **(1.5.3)** *in situ* reaction of azolium salts with a base in presence of silver salt, (Wang and Lin, 1998), **(1.5.4)** transmetallation from a tungsten NHC to silver (Ku et al., 1999).

1.5.1 Free carbene route

The first silver(I) *N*-heterocyclic carbene complex was synthesized by this route in 1993 (Figure 1.13) (Arduengo et al., 1993). According to this method, deprotonation of azolium salts was accomplished by a strong base (like KH or KO*t*Bu) and free NHC was subsequently reacted with the silver source. Following Arduengo, several silver(I)-NHC complexes have been reported using this method (Caballero et al., 2001a; Caballero et al., 2001b; Chung, 2002; Fox et al., 2002). Currently, this method is not popular due to strict reaction conditions and decomposition of some specific azolium salts (Caballero et al., 2001a; Caballero et

al., 2001b; César et al., 2002; Chen et al., 2002; Guerret et al., 2000; McGuinness and Cavell, 2000; Wang et al., 2004).




Figure 1.13: Syntheses of first silver *N*-heterocyclic carbene complex (1993).

1.5.2 Base in the presence of a silver salt

This method was first reported by Wang and Lin in 1998 (Wang and Lin, 1998). These researchers used a basic phase transfer catalyst to synthesize **VII** from benzimidazolium bromide in presence of AgBr (Figure 1.14). However, this procedure was proved unsuccessful for other imidazolium salts (Tulloch et al., 2000).




Figure 1.14: Wang and Lin's method of base in presence of silver salt.

1.5.3 Transmetalation to silver(I)-NHC complexes

This method was proposed by Liu and co-workers in 1998 (Liu et al., 1998). However, transmetalation from tungsten(0) *N*-heterocyclic carbene complexes to silver was achieved in 1999 (Ku et al., 1999; Liu and Reddy, 1999). Although the claimed compounds could neither be isolated nor structurally characterized, however spectroscopic evidences indicated the successful transformations. This method was largely abandoned because silver NHC complexes generated from this method were found to be sensitive to moisture, which is not the characteristic of silver NHC complexes. Later on, transmetalation from other metal centers (Mo(0), Cr(0), Rh(I), Pd(II), Pt(II)) was suggested but sufficient spectroscopic or structural evidences couldn't be generated to substantiate this assertion (Chen et al., 2001; Liu and Reddy, 1999).




Figure 1.15: Transmetalation from tungsten(0) NHC to Ag and dissociation of silver complexes.

1.5.4 “Silver Base” route

This is the most widely used method for the syntheses of silver-NHC complexes. In this method deprotonation and coordination phenomenon occurs spontaneously in a single step.

This method was first reported by Wang and Lin in 1998 using Ag_2O (Figure 1.16) (Wang and Lin, 1998). A detailed mechanism for these reactions has been described by Hayes and co-workers (Hayes et al., 2007).






Figure 1.16: Syntheses of silver *N*-heterocyclic carbene complexes using silver oxide.

Other silver bases such as AgOAc and Ag_2CO_3 have also been reported successfully (Figure 1.17). For example, the use of AgOAc was first introduced by Bertrand and colleagues by reporting the first silver NHC polymer (Scheme 1.15a) (Guerret et al., 2000; Guerret et al., 1997). Tulloch et al., reported a series of silver NHC complexes of structure shown in Scheme 1.15b by using Ag_2CO_3 as metallation agent (Tulloch et al., 2000). The use of Ag_2CO_3 was also successfully employed by

others (Van Veldhuizen et al., 2002). However, reaction durations using this reagent were reported to be longer than reaction times using Ag_2O (Tulloch et al., 2000).



(a)



(b)

Figure 1.17: (a) Syntheses of silver-NHC polymer using AgOAc and (b) Syntheses of bridging complexes using Ag_2CO_3 .

Literature shows that in this route the most frequently used “metal base” is silver oxide (Baker et al., 2005; Bonnet et al., 2003; Catalano et al., 2004; Chianese et al., 2004; Chiu et al., 2005; De Frémont et al., 2005; Frøseth et al., 2005; Herrmann et al., 2004; Hu et al., 2004; Lee et al., 2004; Liu et al., 2003; Mata et al., 2004; Mayr et al., 2004; Melaiye et al., 2004; Quezada et al., 2004; Ramírez et al., 2005; Ramnial et al., 2003; Sentman et al., 2005; Simons et al., 2003; Tulloch et al., 2000; Wang and Lin, 1998; Wanniarachchi et al., 2004) because the reactions can be easily monitored by the uptake of unreacted silver oxide and found to be faster than using other bases.

The reactions of silver oxide with azolium salts have been carried out successfully in solvents, such as dichloromethane, 1,2-dichloromethane, DMSO, acetone, methanol, acetonitrile, DMF, and water. Hence, in present study “Silver Base” route was adopted with minor modifications.

1.6 Applications of silver(I)-NHC complexes

1.6.1 Ligand transfer chemistry

Many NHC complexes are synthesized directly from the azolium salts by deprotonation and subsequently reacting with the desired metals. However, many ligands fail to metalate directly. Many researchers used silver(I)-NHC complexes for the purpose of transferring metal center to the other metals of interest. Transmetalation reactions using silver(I)-NHC can be carried out under aerobic conditions and even in the presence of moisture. To the date, transmetalation using silver(I)-NHC complexes has been successfully achieved for a variety of metals: Au(I), Cu(I), Cu(II), Ni(II), Pd(II), Pt(II), Rh(I), Rh(III), Ir(I), Ir(III), Ru(II), Ru(III), and Ru (IV). The metal to which silver(I)-NHC complexes are most widely transferred is perhaps palladium, where a variety of Pd reagents have been used for transmetalation: Pd(cod)Cl₂, (César et al., 2002; Danopoulos et al., 2003; Frøseth et al., 2003; Magill et al., 2001; Tulloch et al., 2003) Pd(cod)Br₂, (Tulloch et al., 2003) Pd(cod)CH₃Cl, (McGuinness and Cavell, 2000; Neilson et al., 2012; Tulloch et al., 2003) PdCl₂, (Chiu et al., 2005; Lee et al., 2004; Lee et al., 2005) PdCl₂(PhCN)₂ (Simons et al., 2003).

1.6.2 Catalysis

Silver(I)-NHC complexes have also been studied for their catalytic potential. However, compared to the other M-NHC complexes (M = Pd, Ru, Ni, Ir, Rh) (Herrmann, 2002) very few studies have been reported for silver(I)-NHC complexes. Ramirez and co-workers were the first to study the catalytic activity of silver(I)-NHC complexes (Ramírez et al., 2005). They reported the catalytic use of silver complexes for diboration reactions with terminal and internal alkenes. Sentman et al., and Bonnet et al., studied catalytic activity of silver(I)-NHC complexes for ring opening polymerization of L-lactide (Bonnet et al., 2004; Sentman et al., 2004). This area is not that widespread for this class of compounds.

1.6.3 Biological

1.6.3.1 Silver a medically important metal

Silver is a medically valuable metal. Early civilizations used this metal to purify and store water (Russell and Hugo, 1994). Silver nitrate was frequently used as antimicrobial long before 18th century and it was well recognized as an antiseptic in wound care for more than 200 years (Lansdown, 2004). In the 19th century, another useful medicinal application of silver compounds was explored i.e., at very low concentrations, silver compounds were found to kill certain microorganisms (Russell and Hugo, 1994; V. Von Nageli, 1893). In 1881, Créde introduced the use of 1% silver nitrate solution to prevent the eye infections in newborns (Lansdown, 2004). The method is still in use today. The use of colloidal silver solutions to avoid the irritation associated with silver nitrate was introduced in early 20th century (Gibbs, 1999; Lansdown, 2002b). This method remained valid until 1940s. The silver compounds gradually lost interest following the discovery of penicillin and few other

new antibiotics (Lansdown, 2004). Then in 1965, the use of 0.5% silver nitrate solution for the treatment of burn wounds by Moyer (Moyer et al., 1965) re-established the medicinal interest of silver. Moreover in 1968, the discovery of silver sulfadiazine was the true revival of silver antibiotics (Fox, 1968).

In the 21st century, organic and inorganic silver compounds have been introduced in wound dressings (Graham, 2005; Tomaselli, 2006). Silver has been utilized in several different kinds of wound dressings including nylon fabrics, meshes, biodegradable colognes, low adherent materials, carbon fibers, and hydrofiber alginates (Graham, 2005; Lansdown, 2004). These silver containing dressings have been used in the treatment of acute and chronic wounds, leg ulcers and several degrees of burn wounds (Graham, 2005).

The pure silver metal is inactive; whereas, in the presence of moisture, silver readily ionizes to generate silver cations, which then show antimicrobial activity (Lansdown, 2002a; Lansdown, 2004). Furthermore, the activity of silver cations in living systems depend on their bioavailability (Silver, 2003) that is further dependent on delivery methods, solubility, ionization of silver sources and the presence of biologically compatible ligands (Melaiye et al., 2004; Silver, 2003).

1.6.3.2 Benzimidazole: a medically important heterocyclic moiety

Benzimidazole is an aromatic organic compound, composed of benzene ring fused with imidazole (Figure 1.18). Its empirical formula and molecular weight is $C_7H_6N_2$ and 118.14 g/mol respectively. Benzimidazole is a medically important heterocyclic moiety. For example, *N*-ribosyl-dimethylbenzimidazole is a naturally occurring derivative of benzimidazole which serves as an axial ligand for cobalt in vitamin B₁₂ (Barker et al., 1960). This makes benzimidazole a biologically accepted pharmacophore in the field of medicinal chemistry as its derivatives are structural isomers of naturally occurring nucleotides, which makes them compatible with the biopolymers of the living systems (Narasimhan et al., 2012).




Figure 1.18: Representation of benzimidazole moiety and numbering.

This biological compatibility of benzimidazole has created interest in researchers to synthesize its organic derivatives and to screen them for biological activities. To the date, a number of benzimidazole derivatives have been successfully synthesized and tested as protein kinase CK2 inhibitors (Andrzejewska et al., 2003; Pagano et al., 2004), tyrosine kinase inhibitors (Zien et al., 2003), and topoisomerase inhibitors (McBride et al., 2006; Pinar et al., 2004). Benzimidazole was also found active against a wide variety of pathogenic viruses, for example benzimidazoles have shown good results as antiviral (De Clercq and Naesens, 2006; Starcevic et al., 2007),

antihepatitic (Ishida et al., 2006; Li et al., 2007), anti-HIV (Middleton et al., 2004), antienteroviral (Ramla et al., 2007a), anti-RSV (Andries et al., 2003), antibacterial (Goker et al., 2005; He et al., 2003; Kumar et al., 2002), antifungal (Goker et al., 2002; Kawasaki et al., 2003), antianthelmintic (Mavrova et al., 2006), antiamoebic (Lopez-Vallejo et al., 2007; Sondhi et al., 2002), antiprotozoal (Andrzejewska et al., 2004; Ismail et al., 2004), and antimycobacterial (Klimesova et al., 2002) agents. Benzimidazoles have also been tested for diabetes (Minoura et al., 2004), hypertension (Estrada-Soto et al., 2006), inflammation (Mader et al., 2008; Snow et al., 2007) and allergy (Nakano et al., 2000).

In the last decade, very few benzimidazole derivatives were tested against cancer. For example, compound **VIII**, as shown in Figure 1.19, was tested against MCF-7 (breast cancer), HL-60 (Leukemia), HT-29 (Human colon carcinoma), and PC-3 (Prostate cancer) whereas **IX** against HT-29 only (Kumar et al., 2002; Vedula et al., 2003). Compound **X** was tested against A-549 (Human lungs carcinoma), BFTC-905 (Bladder carcinoma), RD (Human embryo rhabdomyosarcoma), MES-SA (Human sarcoma carcinoma), and HeLa (Cervical cancer) cancer cell lines showed better results than UK-1 analogues (Huang et al., 2006). Compound **XI** was tested against Epstein-Barr virus early antigen (EBV-EA) and was found potentially active (Ramla et al., 2007b).




Figure 1.19: Benzimidazole derivatives tested against various types of cancer.

However, on the basis of literature, *it was found that benzimidazolium salts have never been tested against any type of cancer. This research also fills up this area of gap.*

1.6.3.3 Cancer and metal-based drugs

Cancer is the uncontrolled growth of abnormal cells in a living system that initially induces tumor (Figure 1.20). If not treated properly, a tumor invades in the nearby parts of the body and hampers the normal functions of other cells. This

process continues which leads to a number of ailments and in some cases death. A detailed introduction of cancer is beyond the scope of this thesis.




Figure 1.20: Diagram showing malignant tumor.

Beside the fact that cancer is curable at initial stages, it has however become one of the most fatal diseases as the mortality rate due to cancer is increasing worldwide. According to the global cancer statistic report, in 2002, 10.9 million new cancer cases were registered all around the world and 6.7 million patients died, whereas within the next five years (2008) this number increased to 12.6 million new cases and 7.5 million deaths. A rapid development in anti-cancer drug discovery has become substantial (Parkin et al., 2005).

Different therapeutic options like chemotherapy, radiotherapy and surgery are now extensively used to cure different types of cancer. In chemotherapy, the exploration of cisplatin (Figure 1.21) as an anticancer agent by Rosenberg and co-workers is perhaps the first historical example of metal-based anticancer drugs

(Rosenberg et al., 1965; Rosenberg et al., 1967; Rosenberg et al., 1969). However, the severe side effects (nephrotoxicity, neurotoxicity, and ototoxicity) confined its applications. In addition, its poor solubility in water, chemical incompatibility to thiols, and natural or developed resistance of some tumours towards cisplatin further decreased its medicinal worth (Lippert, 1999). However, discovery of cisplatin provided an opportunity to further explore the metal-based anticancer drugs. Later on, a number of cisplatin analogous compounds were synthesized and biologically evaluated but only few of them proved to have pharmacological advantages over cisplatin and are being used worldwide for tumor therapy (Figure 1.21) (Wheate et al., 2010).




Figure 1.21: Worldwide approved platinum-based anticancer drugs.

Platinum based drugs are now so frequently used that only oxaliplatin is expected to cross 2 billion Euros business in the next two years (Berners-Price, 2011). This drug was recently approved to be used as a second line therapy in metastatic colorectal cancer and showed minor side effects so far which can be

treated symptomatically. In addition to platinum, a wide range of transition-metal drugs have been at various stages of development (Alessio, 2011; Gasser et al., 2011; Hannon, 2007).




Figure 1.22: Examples of some transition metal complexes having potential anticancer properties.

For example (Figure 1.22), two ruthenium based drugs, NAMI-A and KP1019 have been in preclinical and clinical phase I and II (Hartinger et al., 2008; Rademaker-Lakhai et al., 2004); two titanium based drugs, Budotitane and Titatocene have also been reported in phase I and II respectively (Abeyasinghe and Harding, 2007); an iron based drug, Ferrocifen is in its preclinical formulation studies (Vessières et al., 2005); a gold complex, $[\text{Au}(\text{dppe})]^+$ was subjected to preclinical studies in late 1986. However, none of these could pass all the stages of clinical development until today.

Recently, metal-NHCs appeared as a rapidly growing field of research in medicinal chemistry. This is also evident from several recent research reports, reviews and patents (Chardon et al., 2012; Eloy et al., 2012; Gasser and Metzler-Nolte, 2012; Gautier and Cisnetti, 2012; Haque et al., 2013; Liu and Gust, 2013; Medvetz et al., 2008a; Monteiro et al., 2012; Oehninger et al., 2013; Teyssot et al., 2009a; Wang et al., 2011).

1.6.3.4 Silver(I)-NHC complexes as potential anti-cancer metallodrugs

Silver(I)-NHC complexes have been widely tested for their antimicrobial activities (Kascatan-Nebioglu et al., 2007). However, they were rarely studied for their anticancer activity (Teyssot et al., 2009a), until recently.

In this regard, Youngs, Tacke and Gautier's research teams are at the forefront. Youngs recently reported anticancer properties of a series of Ag(I)-NHC complexes of structures NHC-Ag-OAc and NHC-Ag-NHC on various cell lines (Medvetz et al., 2008b; Siciliano et al., 2011). These complexes were found to be efficient on OVCAR-3 (ovarian cancer) and MB157 (breast cancer) cells whereas no